Point72 Middle East FZE’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-17,800
Closed -$2.76M 8
2023
Q4
$2.76M Sell
17,800
-52,600
-75% -$7.67M 0.08% 326
2023
Q3
$10.5M Buy
70,400
+2,800
+4% +$411K 0.34% 62
2023
Q2
$9.11M Buy
67,600
+59,400
+724% +$8.71M 0.25% 96
2023
Q1
$1.31M Sell
8,200
-6,400
-44% -$978K 0.04% 428
2022
Q4
$2.36M Buy
+14,600
New +$2.24M 0.1% 263

Other funds holding ABBV

Point72 Middle East FZE's ABBV Position: Q1 2024 in Review

Point72 Middle East FZE sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 125,199 shares — an estimated $19.4M sold.

Point72 Middle East FZE first reported a position in ABBV in Q2 2023 and held it in 3 quarters. The position peaked at $27.6M in Q3 2023. 3,380 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

  • Point72 Middle East FZE reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 125,199 AbbVie shares in Q1 2024, an estimated $19.4M.
  • Point72 Middle East FZE first reported a position in AbbVie in Q2 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's AbbVie position peaked at $27.6M in Q3 2023.
  • 3,380 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.